GlaukosGKOS
GKOS
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 40
20% more capital invested
Capital invested by funds: $7.13B [Q3] → $8.57B (+$1.44B) [Q4]
4.75% more ownership
Funds ownership: 108.66% [Q3] → 113.41% (+4.75%) [Q4]
2% more funds holding
Funds holding: 312 [Q3] → 317 (+5) [Q4]
8% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 106
0% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]
29% less call options, than puts
Call options by funds: $46.1M | Put options by funds: $64.7M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$160
65%
upside
Avg. target
$179
84%
upside
High target
$200
106%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Larry Biegelsen 36% 1-year accuracy 17 / 47 met price target | 65%upside $160 | Overweight Maintained | 21 Feb 2025 |
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target | 81%upside $176 | Buy Maintained | 21 Feb 2025 |
Mizuho Anthony Petrone 45% 1-year accuracy 10 / 22 met price target | 106%upside $200 | Outperform Upgraded | 19 Feb 2025 |
Piper Sandler Matt O'Brien 40% 1-year accuracy 20 / 50 met price target | 85%upside $180 | Overweight Reiterated | 27 Jan 2025 |
Financial journalist opinion
Based on 3 articles about GKOS published over the past 30 days
Positive
Zacks Investment Research
1 day ago
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
Positive
Zacks Investment Research
2 weeks ago
Here's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Neutral
Business Wire
3 weeks ago
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Topcon Healthcare, Inc., RadiusXR, and Glaukos Corporation (NYSE: GKOS) announced a new collaboration and the launch of RadiusXR's new wearable vision testing platform - Inspire®. This collaboration unites RadiusXR's innovative visual field platform and Topcon Healthcare's global leadership in robotic diagnostics and digital healthcare solutions with Glaukos' commitment to expanding patient access by democratizing the diagnosis of ophthalmic diseases such a.
Neutral
Zacks Investment Research
1 month ago
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?
Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year increase. This growth was driven by strong demand for its innovative glaucoma and corneal health solutions.
Positive
Benzinga
1 month ago
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
On Monday, Glaukos Corporation GKOS received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review.
Neutral
Business Wire
1 month ago
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment.
Positive
Benzinga
1 month ago
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition
On Thursday, Glaukos Corp GKOS reported fourth-quarter sales of $105.5 million, up 28% year over year and beating the consensus of $100.49 million.
Negative
Zacks Investment Research
1 month ago
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline
Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
Neutral
Seeking Alpha
1 month ago
Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President, Investor Relations and Corporate Affairs Tom Burns - Chairman and Chief Executive Officer Joe Gilliam - President and Chief Operating Officer Conference Call Participants Tom Stephen - Stifel Richard Newitter - Truist Securities Allen Gong - JPMorgan Michael Sarcone - Jefferies Mason Carrico - Stephens Anthony Petrone - Mizuho Danielle Antalffy - UBS Operator Welcome to Glaukos Corporation's Fourth Quarter and Full-Year 2024 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today are available at www.glaukos.com.
Negative
Zacks Investment Research
1 month ago
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.63 per share a year ago.
Charts implemented using Lightweight Charts™